A review of the resistance mechanisms underlying dabrafenib/trametinib combined therapy in the treatment of BRAF mutant metastatic melanoma
Abstract Background: BRAF mutant metastatic melanoma treatment is most effective when it targets the changes induced within the mitogen-activated protein kinase (MAPK) cas-cade. However, due to the cancer’s heterogeneous nature, …